Featuring perspectives from Dr John N Allan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, including the following topics:

• Introduction (0:00)
• First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) (11:44)
• The Impact of Comorbid Conditions on the Choice of First-Line Therapy for Newly Diagnosed CLL (18:08)
• Toxicities and Other Practical Considerations with Venetoclax-Based Treatment (25:17)
• The Selection and Sequencing of Therapies for Relapsed/Refractory CLL (35:45)
• The Tolerability of Available Bruton Tyrosine Kinase (BTK) Inhibitors (40:43)
• The Potential Role of Therapy Combining BTK Inhibitors and Venetoclax (48:48)
• Bispecific Antibodies as a Treatment Option for Non-Hodgkin Lymphoma (1:04:19)
• Cytokine Release Syndrome and Neurotoxicity with Bispecific Antibodies (1:06:25)
• Other Tolerability and Toxicity Issues with Bispecific Antibody Therapy (1:10:44)
• Bispecific Antibodies for the Management of Follicular Lymphoma (1:18:19)
• The Role of Bispecific Antibody Therapy in the Treatment of Diffuse Large B-Cell Lymphoma (1:24:17)
• Other Practical Considerations with the Use of Bispecific Antibodies (1:40:59)

NCPD information and select publications

Featuring perspectives from Dr William J Gradishar, Dr Virginia Kaklamani, Dr Erica Mayer and Dr Seth Wander, including the following topics:

• Introduction (0:00)
• Addition of Ovarian Function Suppression (OFS) to Adjuvant Endocrine Therapy for Premenopausal Patients with Hormone Receptor (HR)-Positive Breast Cancer — Dr Gradishar (4:49)
• Case: A woman in her mid 20s with HR-positive, HER2-positive intraductal carcinoma (IDC) who received ovarian suppression with TAC chemotherapy and concurrent trastuzumab/pertuzumab followed by tamoxifen (30:48)
• Case: A woman in her late 30s with HR-positive, HER2-negative IDC and no nodal involvement who received postoperative chemoradiation therapy followed by tamoxifen and is considering ovarian suppression (39:31)
• Role of OFS in Preserving Fertility and/or Ovarian Function in Premenopausal Patients – Dr Mayer (44:55)
• Case: A woman in her early 30s with HR-positive, HER2-positive (IHC 3+) IDC recommended to receive perioperative TCHP who is interested in fertility preservation (1:11:15)
• Case: A woman in her mid 30s presenting with ER-positive, HER2-negative breast cancer during early pregnancy who received preoperative TAC and had pathologic complete response at surgery (1:14:18)
• Tolerability and Toxicity of OFS – Dr Kaklamani (1:21:21)
• Case: A woman in her mid 30s, uninterested in fertility preservation, who received chemotherapy and TAC followed by tamoxifen and abemaciclib for ER-positive, HER2-negative breast cancer (1:39:42)
• Case: A premenopausal woman in her late 40s with a 3.6-cm breast tumor and a Recurrence Score (RS) of 26 who becomes amenorrheic with chemotherapy and TC (1:43:32)
• Other Practical Considerations in the Application of OFS – Dr Wander (1:46:29)
• Case: A woman in her early 50s with HR-positive, HER2 IHC 2+ invasive lobular carcinoma and a RS of 15 who declined chemotherapy and opted to stop adjuvant leuprolide after 1 year (1:59:56)
• Case: A woman in her early 40s with HR-positive, HER2 IHC 1+ breast cancer who has no interest in fertility preservation and significant residual disease at surgery (2:14:06)

CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer | Faculty Presentation 2: Therapeutic Approaches for Patients with NSCLC and Other Actionable Genomic Alterations — Justin F Gainor, MD

CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer | Faculty Presentation 1: Management of Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation — Karen Reckamp, MD, MS

CME information and select publications

Featuring perspectives from Dr Justin F Gainor and Dr Karen Reckamp, including the following topics:

• Introduction: Bringing Research into Practice (0:00)
• EGFR Activating Mutations (14:01)
• Exon 20 Insertion Mutations (38:06)
• MET Exon 14 Alterations (41:49)
• HER2 Mutations and Overexpression (50:27)

CME information and select publications

Featuring perspectives from Ms Deanna A Griffie, Ms Caroline Kuhlman, Dr Manish A Shah and Dr John Strickler, including the following topics:

• Introduction (0:00)
• The Current Role of Anti-PD-1/PD-L1 Antibodies in the Management of Nonmetastatic Gastroesophageal Cancers (11:30)
• The Potential Role of Immune Checkpoint Inhibitors (ICIs) as Neoadjuvant Therapy for Patients with Gastric/Gastroesophageal Junction Cancer (20:53)
• First-Line Therapy for Metastatic Gastroesophageal Cancers (36:16)
• The Potential Role of Therapy Targeting Claudin 18.2 for Gastroesophageal Cancers (42:16)
• Targeted Therapies for HER2-Positive Gastroesophageal Cancers (51:42)
• Selection of Appropriate Candidates with Localized Colorectal Cancer (CRC) for Adjuvant Therapy (1:14:24)
• The Current Role of ICIs in the Treatment of Metastatic CRC (mCRC) (1:23:32)
• Tolerability and Other Practical Considerations with ICIs (1:25:57)
• The Role of TAS-102/Bevacizumab in the Management of Relapsed/Refractory (R/R) mCRC (1:36:14)
• The Potential Role of KRAS-Targeted Therapy in the Management of mCRC (1:44:36)

NCPD information and select publications

Featuring perspectives from Dr Matthew D Galsky and Dr Ashish M Kamat, including the following topics:

• Introduction: Urologist for Life (0:00)
• Non-Muscle-Invasive Urothelial Bladder Cancer (UBC) Update (9:54)
• Enfortumab Vedotin/Pembrolizumab Now and in the Future (30:21)
• HER2-Positive UBC (37:33)
• Future Directions — ctDNA (55:39)

CME information and select publications

Featuring perspectives from Ms Ilene Galinsky, Dr Andrew T Kuykendall, Dr Sara M Tinsley-Vance and Dr Abdulraheem Yacoub, including the following topics:

• Introduction (0:00)
• The Biology of Myelofibrosis (MF) (14:00)
• Role of Available and Investigational JAK inhibitors for the Management of MF (45:49)
• Promising Agents and Strategies for Patients with MF (1:23:17)

NCPD information and select publications